Compound probiotics and triple therapy versus bismuth based quadruple therapy: a non-inferiority study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200058491

Enrollment

Unknown

Registered

2022-04-10

Start date

2022-04-01

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Experimental group:Compound probiotics and triple therapy with 14 days

Control group:bismuth based quadruple therapy with 14 days

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Positive 13C urea breath test (13C-UBT), gastric cancer ruled out by gastroscopy; 2. No previous treatment for Helicobacter pylori; 3. Age 18-70 years (including 18 and 70 years).

Exclusion criteria

Exclusion criteria: 1. Subjects who have been treated for Helicobacter pylori before; 2. Those who have taken antibiotics, proton pump inhibitors, H2 receptor antagonists, bismuth preparations and certain antibacterial drugs 4 weeks before enrollment; 3. Patients with a history of major gastrointestinal surgery or bleeding, perforation, obstruction, cancer and other complications; 4. Patients with relevant drug allergy history or contraindications; 5. Patients with other serious diseases; 6. The researchers of this trial.

Design outcomes

Primary

Measure	Time frame
H.pylori eradication rate;	—

Secondary

Measure	Time frame
the rate of side effects;symptom remission rate;Gastric flora and intestinal flora;	—

Countries

China

Contacts

Public ContactYe Chen

Shenzhen Hospital of Southern Medical University

yechen_fimmu@163.com+86 13922293223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026